Transgenic animal models in toxicology: historical perspectives and future outlook.

Toxicology and Environmental Research and Consulting, The Dow Chemical Company, Midland, Michigan 48674, USA.
Toxicological Sciences (Impact Factor: 4.33). 03/2011; 121(2):207-33. DOI: 10.1093/toxsci/kfr075
Source: PubMed

ABSTRACT Transgenic animal models are powerful tools for developing a more detailed understanding on the roles of specific genes in biological pathways and systems. Applications of these models have been made within the field of toxicology, most notably for the screening of mutagenic and carcinogenic potential and for the characterization of toxic mechanisms of action. It has long been a goal of research toxicologists to use the data from these models to refine hazard identification and characterization to better inform human health risk assessments. This review provides an overview on the applications of transgenic animal models in the assessment of mutagenicity and carcinogenicity, their use as reporter systems, and as tools for understanding the roles of xenobiotic-metabolizing enzymes and biological receptors in the etiology of chemical toxicity. Perspectives are also shared on the future outlook for these models in toxicology and risk assessment and how transgenic technologies are likely to be an integral tool for toxicity testing in the 21st century.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The use of genetically modified (GM) mice to assess carcinogenicity is playing an increasingly important role in the safety evaluation of chemicals. While progress has been made in developing and evaluating mouse models such as the Trp53(+/-), Tg.AC and the rasH2, the suitability of these models as replacements for the conventional rodent cancer bioassay and for assessing human health risks remains uncertain. The objective of this research was to evaluate the use of accelerated cancer bioassays with GM mice for assessing the potential health risks associated with exposure to carcinogenic agents. We compared the published results from the GM bioassays to those obtained in the National Toxicology Program's conventional chronic mouse bioassay for their potential use in risk assessment. Our analysis indicates that the GM models are less efficient in detecting carcinogenic agents but more consistent in identifying non-carcinogenic agents. We identified several issues of concern related to the design of the accelerated bioassays (e.g., sample size, study duration, genetic stability and reproducibility) as well as pathway-dependency of effects, and different carcinogenic mechanisms operable in GM and non-GM mice. The use of the GM models for dose-response assessment is particularly problematic as these models are, at times, much more or less sensitive than the conventional rodent cancer bioassays. Thus, the existing GM mouse models may be useful for hazard identification, but will be of limited use for dose-response assessment. Hence, caution should be exercised when using GM mouse models to assess the carcinogenic risks of chemicals.
    Critical Reviews in Toxicology 09/2013; 43(8):611-31. · 6.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Discovery of novel drugs, treatments, and testing of consumer products in the field of dermatology is a multi-billion dollar business. Due to the distressing nature of many dermatological diseases, and the enormous consumer demand for products to reverse the effects of skin photodamage, aging, and hair loss, this is a very active field. Areas covered: In this paper, we will cover the use of animal models that have been reported to recapitulate to a greater or lesser extent the features of human dermatological disease. There has been a remarkable increase in the number and variety of transgenic mouse models in recent years, and the basic strategy for constructing them is outlined. Expert opinion: Inflammatory and autoimmune skin diseases are all represented by a range of mouse models both transgenic and normal. Skin cancer is mainly studied in mice and fish. Wound healing is studied in a wider range of animal species, and skin infections such as acne and leprosy also have been studied in animal models. Moving to the more consumer-oriented area of dermatology, there are models for studying the harmful effect of sunlight on the skin, and testing of sunscreens, and several different animal models of hair loss or alopecia.
    Expert Opinion on Drug Discovery 01/2013; · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Glutathione S-transferases (GSTs) are Phase II drug-metabolizing enzymes that catalyze the conjugation of electrophilic compounds to glutathione. This reaction generally detoxifies reactive metabolites of xenobiotics, such as drugs and environmental chemicals, and therefore, GSTs are considered toxicologically important enzymes. Human GST genes display genetic polymorphisms, and the impact of null genotypes of GST Mu 1 (GSTM1) and GST Theta 1 (GSTT1) have been extensively studied. Recently, corresponding Gstm1- and Gstt1-null mice have been developed. Areas covered: This review covers GSTM1- and GSTT1-null genotypes in humans and utilization of Gstm1- and Gstt1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity (ADMET) studies. Furthermore, the possibility of Gstm1- and Gstt1-null mice as models of humans with GSTM1- and GSTT1-null genotypes is discussed. Expert opinion: The experimental approach to assess the impact of GSTM1- and GSTT1- null genotypes on ADMET is very limited so far. Gstm1- and Gstt1-null mice have potential as human models, since null genotypes of GSTM1/Gstm1 and GSTT1/Gstt1 decreased hepatic GST activities toward p-nitrobenzyl chloride and dichloromethane, respectively, in both humans and mice. This suggests functional similarity of GSTM1 and GSTT1 toward some substrates between humans and mice.
    Expert Opinion on Drug Metabolism &amp Toxicology 03/2013; · 2.94 Impact Factor